Formyl Peptide Receptor-Like 1 Agonist, WKYMVm

A potent chemoattractant that enhances leukocyte activity via activation of Formyl Peptide Receptor-Like 1 (FPRL1). More poteut than fmlp at inducing neutrophil chemotaxis, neutrophil complement receptor 3. Shown to activate phospholipase C-mediated inositol phosphate formation in human U266 myeloma cells (EC₅₀ = 510 pM) and in U937 and HL60 cells. Has no effect inositide phosphate synthecs in a variety of other cell lines (e.g. NIH3T3, PC12, Daudi, Sp2, Jurkat, H9, Molt-4, SupT-1, K562, and RBL-2H3). Radioiodinatable at the tyrosine residue.

A potent chemoattractant that enhances leukocyte activity via activation of Formyl Peptide Receptor-Like 1 (FPRL1). Shown to activate phospholipase C-mediated inositol phosphate formation in human U266 myeloma cells (EC₅₀ = 510 pM). Also shown to stimulate inositol phosphate formation in U937 and HL60 cells, but has no effect on a variety of other cell lines (e.g. NIH3T3, PC12, Daudi, Sp2, Jurkat, H9, Molt-4, SupT-1, K562, and RBL-2H3). Stimulates phagocyte chemotaxis and [Ca²⁺] flux, and is more effective than fMLP (Cat. No. 05-22-2500) in generating superoxide in human neutrophils. Radioiodinatable at the tyrosine residue.

Cell permeable: no

EC50 = 510 pM in activating phospholipase C-mediated inositol phosphate formation in human U266 myeloma cells

Primary Target
Formyl Peptide Receptor-Like 1

Product does not compete with ATP.

Reversible: no

Packaged under inert gas

Toxicity: Standard Handling (A)

H-Trp-Lys-Tyr-Met-Val-D-Met-CONH₂

Supplied as a trifluoroacetate salt.

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Bae, Y.S., et al. 2004. J. Immunol.173, 607.
Bae, Y.S., et al. 2003. Mol. Pharmacol.64, 841.
Le, Y., et al. 1999. J. Immunol.163, 6777.
Seo, J.K., et al. 1997. J. Immunol.158, 1895.
Baek, S.H., et al. 1996. J. Biol. Chem.271, 8170.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany